Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide Replacement for Lenalidomide in Relapsed/Refractory MM
NCT02188368Phase 2Terminated
- Sponsor
- ONCOtherapeutics
- Start
- Jul 2014
- Primary completion
- Oct 2020
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide in multiple myeloma (MM) (3 arms), sponsored by ONCOtherapeutics. Primary endpoints: Maximum Tolerated Dose, Number of subjects with adverse events up to 36 months and 2 more. Started Jul 2014; status: terminated.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT02188368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02188368.